(lp0
S'Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B.'
p1
aS'SANGAMO THERAPEUTICS, INC.  Files An 8-K Departure of Directors ... Market Exclusive - Mar 20, 2017 On March 14, 2017, the Compensation Committee of the Board of Directors of Sangamo Therapeutics, Inc.  adopted an Executive Severance Plan .'
p2
aS'Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference ... PR Newswire  - Feb 21, 2017 RICHMOND, Calif., Feb. 21, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the company will release its fourth quarter and full year 2016 financial results before the market&nbsp;...'
p3
aS'Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For ... PR Newswire  - Feb 27, 2017 RICHMOND, Calif., Feb. 27, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, today announced that the U.S.Sangamo  Announces Rare Pediatric Disease Designation From FDA For SB-318 - StreetInsider.com'
p4
aS'Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the U.S.'
p5
aS'4.35 MarketWatch - Dec 21, 2009 Sangamo Therapeutics Inc. Watchlist CreateSGMOAlert. After Hours. Last Updated: Mar 20, 2017 5:38 p.m.. $ 4.35. 0.00 0.00%.'
p6
aS"Sangamo Therapeutics Inc  Receives Buy Rating from Cowen and Company Sports Perspectives - 4 hours ago Sangamo Therapeutics Inc 's stock had its buy rating reaffirmed by research analysts at Cowen and Company in a research note issued on Wednesday.Top Institutional Investors That Own Sangamo Therapeutics, Inc.  - Post AnalystSangamo Biosciences Gets a Buy from Cowen &amp; Co. - Analyst Ratings"
p7
aS'Chart Watch: Checking on Shares of Sangamo Therapeutics Inc  Baxter Review - 15 hours ago Technical traders have a large inventory of technical indicators they may use when doing technical stock analysis. After a recent look, the 14-day ATR for Sangamo Therapeutics Inc  is resting at 0.25. First developed by J. Welles Wilder, the ATR ...'
p8
aS'Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results PR Newswire  - Feb 28, 2017 &quot;Early this year we rebranded our company as Sangamo Therapeutics, underscoring our focus on clinical development of genomic therapies using our industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy,&quot;&nbsp;...SANGAMO THERAPEUTICS, INC.  Files An 8-K Results of Operations ... - Market Exclusive'
p9
aS"BRIEF-Sangamo Therapeutics announces CFO succession Reuters - Feb 27, 2017 SANTIAGO, March 11 The striking union at BHP Billiton's Escondida copper mine in Chile, the world's largest, told Reuters on Saturday that it will not accept an offer from the company to return to the negotiating table, and it called on the company to ..."
p10
a.